

Research and development

Defining, National Revenue Department definition inconclusive, 15:40, 53

See also Brand name drugs—Exclusivity period from imports, Contractual obligations

Intramural/extramural *see* Drugs and pharmaceuticals industry

See also Abbot Laboratories; Aerospace industry; Apotex; Automotive industry; Ayerst Laboratories; Boehringer Ingelheim; Bio-medical research; Brand name drugs; Canadian Diabetes Association; Canadian Drug Manufacturers Association; Cangene Corp.; Ciba-Geigy Canada Ltd.; Diabetes; Diseases—Infectious; Drug Prices Review Board—Reporting responsibilities; Drugs and pharmaceuticals industry; Generic drugs—Industry—Royalty payments; Geriatrics; Health care; Heritage Medical Fund for Research; Hoffman-La Roche Limited; Income tax; Kidney disease; Kidney Foundation of Canada; Medical journals, Canadian; Medical Research Council; Merck Frosst Canada Inc.; Multinational corporations; Multiple sclerosis; Orphan diseases; Pharmaceutical Manufacturers Association of Canada; Provinces—Social services; Saskatchewan—Government; Smith, Kline and French Canada Ltd.; United States; Universities

Restrictive Trade Practices Commission

Report, 3:7; 9:30

See also Drug patents—Abolishing; Drugs and pharmaceuticals—Costs/prices

Reverse onus *see* Drug patents—Product vs process patent

Review boards *see* Disabled and handicapped

Rice, Stanley (Community Health Co-operative Federation of Saskatchewan)

Patent Act (amdt.)(Bill C-22), 11:3, 67-72, 74-5, 77-80

Richardson, Carol (Canadian Council on Social Development)

Patent Act (amdt.)(Bill C-22), 7:3-4, 7, 17-8

Rise and Fall of Montreal, The, 10:12

Roache, Paul (Smith, Kline and French Canada Ltd.)

Patent Act (amdt.)(Bill C-22), 14:3, 34-46

References, background, 14:37

Roberts, Roberta (Canadian Association of Social Workers)

Patent Act (amdt.)(Bill C-22), 11:3, 51-2, 56, 61

Roche, Dr. *see* Canadian Red Cross Society; Medical Research Council—Budget

Roy, Joan (Canadian Association of Social Workers)

Patent Act (amdt.)(Bill C-22), 11:3, 60-1

Royal College of Physicians and Surgeons *see* Drugs and pharmaceuticals industry—Research and development, Clinical

Royalties *see* Brand name drugs—Research and development record; Generic drugs

Salt Lake City, Utah *see* High technology centres—Boulder, Colorado

Saskatchewan

Government

Andre consultations, Bill C-22, 11:23-4

Legislation, Bill C-22 position, 11:24-5, 69

Research and development promises *re* Bill C-22, corporate commitments to province requesting, 11:21-2, 25, 28, 68, 70

See also Drug plans; Drugs and pharmaceuticals—Provinces; Witnesses

Grain farmers, federal subsidy/political gains, 12:69

Saskatchewan Prescription Drug Fund Organization *see* Community Health Co-operative Federation of Saskatchewan

Science Council of Canada *see* Brand name drugs—Exclusivity period from imports, Contractual obligations; Universities—Research and development; Witnesses

Scientific Research Tax Credit Program

Legislation, loopholes, use, 9:15, 19-20; 15:41; 17:23-4

Petroleum Incentives Program comparison, 9:19

See also Drug Prices Review Board; Generic drugs—Royalty payments

Sellers, Edward (Canadian Society of Clinical Pharmacology)

Patent Act (amdt.)(Bill C-22), 15:3, 43-54

Senior citizens

Legislation, Bill C-22 concerns, 1:36; 3:10-1, 19, 21, 24, 43, 73; 6:17, 75; 9:26, 35; 11:53-4, 61; 12:19-20, 22; 14:18-9, 36, 59, 66-7; 15:32, 55-6, 60-1, 63, 65-6, 68

Scare tactics *re* generic drug quality, 15:56-7, 62, 64

United States, Bill C-22 views, 12:23

See also Drug plans

Senneville, Que. *see* Smith, Kline and French Canada Ltd.

Shamrock Summit *see* Patent Act (amdt.)(Bill C-22)—References, Political considerations

Sherman, Bernard (Canadian Drug Manufacturers Association)

Patent Act (amdt.)(Bill C-22), 3:3, 12, 15-24, 29-31, 35-41

References, 3:50-1

Sleeping sickness *see* Diseases—Infectious, Malaria

Smith, Kline and French Canada Ltd.

Attorney General of Canada lawsuit, 14:41-2; 16:69

Background, financial statements, etc., 14:37-40

Glaxo Canada Limited competition, 14:39-40

Research centre, Senneville, Que., closing, 10:12

See also Generic drugs—Intellectual property; Witnesses

Smith, Stuart L. (Science Council of Canada)

Patent Act (amdt.)(Bill C-22), 13:3, 36-46

Socialized medicine *see* Cystic fibrosis

Spero, Dr. L. (Coalition of Scientists, University of Toronto)

Patent Act (amdt.)(Bill C-22), 6:3, 34-47

Stanbury, Prof. William

References, 8:22

Steering committee *see* Procedure and Committee business—Agenda and procedure subcommittee

Steeves, Madeleine (National Federation of Nurses' Unions)

Patent Act (amdt.)(Bill C-22), 9:3, 28, 31, 37

Stelazine *see* Health care—Hospitals, Drug therapy alternatives

Stetler, Mr.

References, 1:37-8

Strayer, Mr. Justice Barry *see* Drug patents—Legislation

Supreme Court of Canada *see* Drug Prices Review Board—Constitutionality

Sweden *see* Drug patents—Abolishing

Tagamet *see* Drugs and pharmaceuticals